Back
 OJU  Vol.4 No.5 , May 2014
Plasma Kinetic Resection of Prostate Combined Terazosin for Treatment of BPH Patient with Coexisting Hypertension
Abstract: Objective: To evaluate the efficacy and safety of terazosin and plasma kinetic resection of the prostate (PKRP) in the treatment of benign prostatic hyperplasia (BPH) patients with coexisting hypertension. Methods: A total of 205 men who suffered from BPH with concomitant hypertension were enrolled in this study. They all received PKRP surgery and terazosin medication from one week before to 3 months after the operation. The procedures of efficacy and safety were evaluated by analysis of the changes in blood pressures, IPSS, Qmax and the drug related adverse events 4 weeks and 3 months after the operation. Results: The systolic blood pressure decreased from 161 ± 12.33 mmHg at baseline to 148 ± 7.27 mmHg four weeks (P < 0.05) and to 132 ± 6.13 mmHg three months after the operation (P < 0.01), the diastolic blood pressure decreased from 102 ± 4.99 mmHg to 95 ± 4.61 mmHg four weeks (P < 0.05) and to 81 ± 4.26 mmHg three months after the operation (P < 0.01). The IPSS reduced from 21 ± 4.82 to 15 ± 3.66 four weeks (P < 0.05) and to 12 ± 3.11 three months after the operation (P < 0.01). The Qmax were improved from 7 ± 4.41 to 12 ± 1.34 four weeks and to 15 ± 2.92 three months after the operation (P < 0.05). There were no notable adverse events. Conclusions: PKRP combined with terazosin in treating BPH with concomitant hypertension patient is a safe and effective procedure with a good patient compliance.
Cite this paper: Zheng, M. , Zeng, M. , Jiang, C. , Chen, J. , Li, S. and Wang, J. (2014) Plasma Kinetic Resection of Prostate Combined Terazosin for Treatment of BPH Patient with Coexisting Hypertension. Open Journal of Urology, 4, 57-62. doi: 10.4236/oju.2014.45010.
References

[1]   Maruenda, J., Bhatnagar, V. and Lowenthal, D.T. (1999) Hypertension in the Elderly with Coexisting Benign Prostatic Hyperplasia. Urology, 53, 7-12. http://dx.doi.org/10.1016/S0090-4295(98)00533-0

[2]   Pinheiro, L.C. and Martins Pisco, J. (2012) Treatment of Benign Prostatic Hyperplasia. Techniques in Vascular and Interventional Radiology, 15, 256-260. http://dx.doi.org/10.1053/j.tvir.2012.09.004

[3]   Guo, L., Zhang, X., Li, P. and Na, Y. (2005) Association Study between Benign Prostatic Hyperplasia and Primary Hypertension. Zhonghua Wai Ke Za Zhi, 43, 108-111.

[4]   Michel, M.C., Heemann, U. and Schumacher, H. (2004) Association of Hypertension with Symptoms of Benign Prostatic Hyperplasia. Journal of Urology, 172, 1390-1393.
http://dx.doi.org/10.1097/01.ju.0000139995.85780.d8

[5]   Nuhoglu, B., Ayyildiz, A., Karagüzel, E. and Germiyano?lu, C. (2006) Plasmakinetic Prostate Resection in the Treatment of Benign Prostate Hyperplasia: Results of 1-Year Follow-Up. International Journal of Urology, 13, 21-24. http://dx.doi.org/10.1111/j.1442-2042.2006.01218.x

[6]   Zhao, X., Sun, X., Liu, Z., Wang, J. and Liu, L. (2006) Comparison of the Results of Transurethral Plasmakinetic Resection versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia. Chinese Journal of Urology, 27, 628-630.

[7]   Kaplan, S.A. and Kaplan, N.M. (1996) Alpha-Blockade: Monotherapy for Hypertension and Benign Prostatic Hyperplasia. Urology, 48, 541-550. http://dx.doi.org/10.1016/S0090-4295(96)00242-7

[8]   Pareek, G., Shevchuk, M., Armenakas, N.A., Vasjovic, L., Hochberg, D.A., Basillote, J.B., et al. (2003) The Effect of Finasteride on the Expression of Vascular Endothelial Growth Factor and Microvessel Density: A Possible Mechanism for Decreased Prostatic Bleeding in Treated Patients. Journal of Urology, 169, 202-231. http://dx.doi.org/10.1016/S0022-5347(05)64025-6

[9]   Walma, E.P. (1997) Withdrawal of Long Term Diuretic Medication in Elderly Patients: A Double Blind Randomized Trial. British Medical Journal, 315, 464-468. http://dx.doi.org/10.1136/bmj.315.7106.464

[10]   Kobayashi, S., Tang, R. and Shapiro, E. (1993) Characterization Localization of Prostatic Alpha l Aderenoceptors Using Radio Ligand Binding on Slide-Mounted Tissue Section. Journal of Urology, 150, 2002-2006.

[11]   Kwak, C., Lee, J.K. and Ku, J.H. (2007) High-Dose Terazosin Therapy (5 mg) in Korean Patients with Lower Urinary tract Symptoms with or Without Concomitant Hypertension: A Prospective, Open-Label Study. Yonsei Medical Journal, 48, 994-1000. http://dx.doi.org/10.3349/ymj.2007.48.6.994

[12]   Roehrborn, C.G., Oesterling, J.E., Auerbach, S., Kaplan, S.A., Lloyd, L.K., Milam, D.E., et al. (1996) The Hytrin Community Assessmeng Trial Study: A One-Year Study of Terazosin versus Placebo in the Treatment of Men with Symptomatic Benign Prostactic Hyperplasia. Urology, 47, 159-168. http://dx.doi.org/10.1016/S0090-4295(99)80409-9

[13]   Du, G., Qi, J., Song, J., Wang, Q., Kong, X., Jin, C., et al. (2010) A Multicenter Prospective Clinical Study on the Effectiveness and Safety of Terazosin in the Treatment of Chinese Benign Prostatic Hyperplasia Patients. Chinese Journal of Urology, 31, 343-346.

[14]   Turkeri, L.N., Oxyurek, M., Ersev, D. and Akda?, A. (2001) Apoptotic Regression of Prostatic Tissue Induced by Short-Term Doxazosin Treatment in Benign Prostatic Hyperplasia. Archivos Espa?oles de Urología, 54, 191-196.

[15]   Glassman, D.T., Chon, J.K., Borkowski, A., Jacobs, S.C. and Kyprianou, N. (2001) Combined Effect of Terazosin and Finasteride on Apoptosis, Cell Proliferation, and Transforming Growth Factor-Beta Expression in Benign Prostatic Hyperplasia. The Prostate, 46, 45-51. http://dx.doi.org/10.1002/1097-0045(200101)46:1<45::AID-PROS1007>3.0.CO;2-U

[16]   Savate, S.J., Spuregen, A.M., Galea, G., Britanico, J. and Vapnek, J.M. (1998) Combination Medical Therapy for Symptomatic Benign Prostatic Hyperplasia. The Canadian Journal of Urology, 5, 578-584.

[17]   Autorino, R., Damiano, R., Di Lorenzo, G., Quarto, G., Perdonà, S., D’Armiento, M., et al. (2009) Four-Year Outcome of a Prospective Randomised Trial Comparing Bipolar Plasmakinetic and Monopolar Transurethral Resection of the Prostate. European Urology, 55, 922-929.
http://dx.doi.org/10.1016/j.eururo.2009.01.028

[18]   Ho, H.S., Yip, S.K., Lim, K.B., Fook, S., Foo, K.T. and Cheng, C.W. (2007) A Prospective Randomized Study Comparing Monopolar and Bipolar Transurethral Resection of Prostate Using Transurethral Resection in Saline (TURIS) System. European Urology, 52, 517-522.
http://dx.doi.org/10.1016/j.eururo.2007.03.038

[19]   Lepor, H., Jones, K. and Williford, W. (2001) The Mechanism of Adverse Events Associated with Terazosin: An Analysis of the Veterans Affairs Cooperative Study. Journal of Urology, 58, 508-516.

[20]   Yang, C. and Yin, X. (2005) Observed Terazosin Efficacy in Perioperative Period of Transurethral Prostatectomy. Shandong Medical Journal, 45, 27.

 
 
Top